SYM2206 is a low-affinity, non-competitive AMPA receptor antagonist (IC50 = 1.6 µM) that demonstrates anticancer properties. It functions by inhibiting Nav1.6-mediated sustained currents, leading to reduced survival in pancreatic cancer cells in vitro, highlighting its utility in neurobiological and oncology research.